Richard M Elledge

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. pmc Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome
    Grazia Arpino
    Breast Center at Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
    Breast Cancer Res 6:R149-56. 2004
  2. ncbi request reprint Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance
    Grazia Arpino
    Breast Center, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA
    J Natl Cancer Inst 97:1254-61. 2005
  3. ncbi request reprint Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers
    Yee Lu Tham
    Breast Center and the Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    Breast Cancer Res Treat 94:279-84. 2005
  4. ncbi request reprint Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer
    Syed K Mohsin
    Breast Center at Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Breast Cancer Res Treat 94:205-11. 2005
  5. pmc Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes
    Mothaffar F Rimawi
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Cancer 116:1234-42. 2010
  6. ncbi request reprint HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study
    Grazia Arpino
    Breast Center, Baylor College of Medicine, Methodist Hospital, Houston, Texas, USA
    Clin Cancer Res 10:5670-6. 2004
  7. ncbi request reprint Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype
    Dang M Nguyen
    Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    Clin Cancer Res 12:5047-54. 2006
  8. ncbi request reprint Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
    Valerie Jeanne Bardou
    Breast Center at Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    J Clin Oncol 21:1973-9. 2003
  9. ncbi request reprint Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome
    Grazia Arpino
    Breast Center at Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer 94:2119-27. 2002
  10. doi request reprint Association of surgery with improved survival in stage IV breast cancer patients
    D Kay Blanchard
    Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
    Ann Surg 247:732-8. 2008

Research Grants

  1. NSABP Participating Sites
    Jenny Chang; Fiscal Year: 2007

Detail Information

Publications18

  1. pmc Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome
    Grazia Arpino
    Breast Center at Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
    Breast Cancer Res 6:R149-56. 2004
    ..In the present study we undertook an extensive comparison of ILC and IDC using a large database to provide a more complete and reliable assessment of their biologic phenotypes and clinical behaviors...
  2. ncbi request reprint Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance
    Grazia Arpino
    Breast Center, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA
    J Natl Cancer Inst 97:1254-61. 2005
    ..We hypothesized that ER+/PR- breast tumors are more likely than ER+/PR+ breast tumors to have an aggressive phenotype, to express HER-1 and overexpress HER-2, and are less likely to benefit from tamoxifen adjuvant therapy...
  3. ncbi request reprint Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers
    Yee Lu Tham
    Breast Center and the Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    Breast Cancer Res Treat 94:279-84. 2005
    ....
  4. ncbi request reprint Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer
    Syed K Mohsin
    Breast Center at Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Breast Cancer Res Treat 94:205-11. 2005
    ..Proliferation, determined by Ki67 staining, was not significantly changed. Clinical trials of this type are difficult to carry out and modifications in trial design are needed to make this process more efficient...
  5. pmc Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes
    Mothaffar F Rimawi
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Cancer 116:1234-42. 2010
    ..We hypothesized that EGFR expression in human breast tumors, when centrally and uniformly assessed, is associated with an aggressive phenotype and resistance to systemic therapy...
  6. ncbi request reprint HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study
    Grazia Arpino
    Breast Center, Baylor College of Medicine, Methodist Hospital, Houston, Texas, USA
    Clin Cancer Res 10:5670-6. 2004
    ..Evidence of resistance from clinical studies has been inconsistent. The present study examined whether HER-2 gene amplification or HER-1 expression predicted response to tamoxifen...
  7. ncbi request reprint Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype
    Dang M Nguyen
    Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    Clin Cancer Res 12:5047-54. 2006
    ..The aims of this study are (a) to prospectively identify differential gene expression patterns associated with IBC and (b) to confirm these pathways using tissue arrays...
  8. ncbi request reprint Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
    Valerie Jeanne Bardou
    Breast Center at Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    J Clin Oncol 21:1973-9. 2003
    ..To determine whether progesterone receptor (PgR) status provides additional value to estrogen receptor (ER) status and improves prediction of benefit from endocrine treatment among patients with primary breast cancer...
  9. ncbi request reprint Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome
    Grazia Arpino
    Breast Center at Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer 94:2119-27. 2002
    ..The objective of this study was to comprehensively characterize the clinical and biologic features of adenoid cystic carcinoma (ACC) and to assess the implications for management in a large cohort of patients...
  10. doi request reprint Association of surgery with improved survival in stage IV breast cancer patients
    D Kay Blanchard
    Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
    Ann Surg 247:732-8. 2008
    ..This study aims to examine the role of surgery in patients with stage IV breast cancer...
  11. ncbi request reprint Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor
    Jenny Chang
    Breast Center at Baylor College of Medicine, Houston, Texas, USA
    Cancer 97:545-53. 2003
    ..Therefore, the authors tested the hypothesis that the characteristics of primary breast tumors are important determinants of prognosis and survival in patients with metastatic breast carcinoma...
  12. ncbi request reprint The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause
    Yee Lu Tham
    Breast Care Center, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas, 77030, USA
    J Support Oncol 4:295-8, 304. 2006
    ..05). More emphasis must be given to educating breast cancer survivors with chemotherapy-induced menopause about bone health and its maintenance. Approved therapies to prevent osteoporosis probably are underused in this population...
  13. ncbi request reprint Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results
    Andrea E Van Pelt
    Department of Surgery, Methodist Hospital, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Clin Breast Cancer 4:348-53. 2003
    ..A high rate of brain metastasis was noted, particularly in patients with baseline metastatic disease...
  14. ncbi request reprint Lobular neoplasia on core-needle biopsy--clinical significance
    Grazia Arpino
    Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    Cancer 101:242-50. 2004
    ..The goal of the current study was to determine the incidence of breast carcinoma at sites of core biopsy exhibiting LN compared with sites of core biopsy exhibiting ADH...
  15. ncbi request reprint Premalignant and in situ breast disease: biology and clinical implications
    Grazia Arpino
    Breast Care Center, Baylor College of Medicine, The Methodist Hospital, Houston, Texas 77030, USA
    Ann Intern Med 143:446-57. 2005
    ..Current clinical management is heterogeneous and depends on histologic examination and individual patient factors. Options for breast cancer risk reduction and prevention are available...
  16. ncbi request reprint A roundtable discussion of aromatase inhibitors as therapy for breast cancer
    D Craig Allred
    Baylor College of Medicine, Houston, Texas, USA
    Breast J 9:213-22. 2003
    ..Finally, recent results suggest that anastrozole may be superior to tamoxifen as adjuvant therapy for early stage disease in postmenopausal women with hormone-responsive disease...
  17. ncbi request reprint Tales from a targeted therapy
    Richard M Elledge
    J Clin Oncol 24:1323-5. 2006
  18. ncbi request reprint Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials
    Anthony Howell
    Department of Medical Oncology, Cancer Research UK, Christie Hospital, Manchester, United Kingdom
    Cancer 104:236-9. 2005
    ..The authors reported the overall survival results from these studies...

Research Grants2

  1. NSABP Participating Sites
    Jenny Chang; Fiscal Year: 2007
    ....